成立18年的苏州瑞博生物技术股份有限公司,在经历科创板折戟四年后,近日向港交所递交招股书,再度冲击资本市场。作为国内最早布局小核酸药物的企业之一,瑞博生物曾因技术光环吸引中金、高瓴等明星资本押注。然而,时至今日,公司仍未实现产品商业化,2023年营收仅4.4万元,2024年虽通过与跨国药企合作收入增至1.43亿元,但两年累计亏损仍高达7.18亿元。目前,公司正面临诸多挑战,包括在研管线研发进展落后...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.